- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Symposium 2024 report: ‘Sepsis – a brighter hope for tomorrow’
- Share
- Tweet
- Share on Facebook
- Share
Volition published a report from its ‘NETs in sepsis management’ symposium at ESICM Lives 2024.
The symposium explored research findings from three large, independent studies involving more than 3,000 sepsis patients. The studies used Nu.Q® NETs to measure levels of circulating H3.1 nucleosomes in the bloodstream, a surrogate marker for Neutrophil Extracellular Traps (NETs).
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields